• Home
  • Ongoing Clinical Studies

Ongoing Clinical Studies

Filter Clinical Studies by:

Name

Physician(s)

Head---Neck-Cancer

Name

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651) ›

Physician(s)

Troy H. Guthrie, Jr., MD

Lung-Cancer

Name

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANAMORELIN HCL FOR THE TREATMENT OF MALIGNANCY ASSOCIATED WEIGHT LOSS AND ANOREXIA IN ADULT PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER ›

Physician(s)

Troy H. Guthrie, Jr., MD

Name

A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer  ›

Physician(s)

Troy H. Guthrie, Jr., MD

Name

LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB ›

Physician(s)

Thomas Boike, MD
Larry L. Kestin, MD, FACR
Alvaro A. Martinez, MD, FACR, FABS, FASTRO
Frank A. Vicini, MD, FACR, FASTRO

Name

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice ›

Physician(s)

Troy H. Guthrie, Jr., MD

Name

PHASE III COMPARISON OF THORACIC RADIOTHERAPY REGIMENS IN PATIENTS WITH LIMITED SMALL CELL LUNG CANCER ALSO RECEIVING CISPLATIN OR CARBOPLATIN AND ETOPOSIDE ›

Physician(s)

John Vito Antonucci, MD
Michael I. Ghilezan, MD, PhD
Larry L. Kestin, MD, FACR
Kay T. Miller, MD
Frank A. Vicini, MD, FACR, FASTRO

Name

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC) ›

Physician(s)

John Vito Antonucci, MD

Lymphoma

Name

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)  ›

Physician(s)

Troy H. Guthrie, Jr., MD

Name

Phase 1/2A Dose Escalation Study in CLL, SLL or NHL ›

Physician(s)

Troy H. Guthrie, Jr., MD

Name

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma ›

Physician(s)

Troy H. Guthrie, Jr., MD

Back
To top